Sequence variations of latent membrane protein 2a in epstein-barr virus-associated gastric carcinomas from guangzhou, southern china

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Han, Jing ^a,c   Chen, Jian ning ^a   Zhang, Zhi gang ^a   Li, Hai gang ^a   Ding, Yun gang ^a,d   Du, Hong ^b   Shao, Chun kui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; EPITOPE; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; UNCLASSIFIED DRUG; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CHINA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; EPSTEIN BARR VIRUS; FEMALE; GENE FUNCTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LMP2A GENE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PROTEIN MOTIF; SEQUENCE ANALYSIS; STOMACH CARCINOMA; VIRUS CARRIER; VIRUS GENE; AGED; CARCINOMA; EXON; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; VIROLOGY;

HUMAN HERPESVIRUS 4;

ADULT; AGED; CARCINOMA; CHINA; EPITOPES; EXONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STOMACH NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 84859046743     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034276     Document Type: Article

References (54)

1. Epstein MA, Achong BG, Barr YM, (1964) Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1: 702-703.
2. Young LS, Rickinson AB, (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757-768.
3. Akiba S, Koriyama C, Herrera-Goepfert R, Eizuru Y, (2008) Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci 99: 195-201.
4. Lee JH, Kim SH, Han SH, An JS, Lee ES, et al. (2009) Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol 24: 354-365.
5. Uozaki H, Fukayama M, (2008) Epstein-Barr virus and gastric carcinoma-viral carcinogenesis through epigenetic mechanisms. Int J Clin Exp Pathol 1: 198-216.
6. Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, et al. (1993) Epstein-Barr virus in gastric carcinoma. Am J Pathol 143: 1250-1254.
7. van Beek J, zur Hausen A, Klein Kranenbarg E, van de Velde CJ, Middeldorp JM, et al. (2004) EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol 22: 664-670.
8. Murphy G, Pfeiffer R, Camargo MC, Rabkin CS, (2009) Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology 137: 824-833.
9. Thompson MP, Kurzrock R, (2004) Epstein-Barr virus and cancer. Clin Cancer Res 10: 803-821.
10. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, et al. (2000) Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 60: 2745-2748.
11. Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, et al. (1996) Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer 74: 625-631.
12. Luo B, Wang Y, Wang XF, Liang H, Yan LP, et al. (2005) Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol 11: 629-633.
13. Fruehling S, Longnecker R, (1997) The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235: 241-251.
14. Wang X, Liu X, Jia Y, Chao Y, Xing X, et al. (2010) Widespread sequence variation in the Epstein-Barr virus latent membrane protein 2A gene among northern Chinese isolates. J Gen Virol 91: 2564-2573.
15. Longnecker R, (2000) Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv Cancer Res 79: 175-200.
16. Miller CL, Lee JH, Kieff E, Longnecker R, (1994) An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A 91: 772-776.
17. Ikeda A, Caldwell RG, Longnecker R, Ikeda M, (2003) Itchy, a Nedd4 ubiquitin ligase, downregulates latent membrane protein 2A activity in B-cell signaling. J Virol 77: 5529-5534.
18. Snyder MD, Pierce SK, (2006) A mutation in Epstein-Barr virus LMP2A reveals a role for phospholipase D in B-Cell antigen receptor trafficking. Traffic 7: 993-1006.
19. Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH, et al. (2010) Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 6: e1000940.
20. Scholle F, Bendt KM, Raab-Traub N, (2000) Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74: 10681-10689.
21. Fukuda M, Longnecker R, (2004) Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol 78: 1697-1705.
22. Hino R, Uozaki H, Inoue Y, Shintani Y, Ushiku T, et al. (2008) Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res 68: 1427-1435.
23. Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, et al. (2009) Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res 69: 2766-2774.
24. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB, (1997) Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 158: 3325-3334.
25. Redchenko IV, Rickinson AB, (1999) Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. J Virol 73: 334-342.
26. Meij P, Leen A, Rickinson AB, Verkoeijen S, Vervoort MB, et al. (2002) Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer 99: 93-99.
27. Whitney BM, Chan AT, Rickinson AB, Lee SP, Lin CK, et al. (2002) Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J Med Virol 67: 359-363.
28. Wang B, Yao K, Liu G, Xie F, Zhou F, et al. (2009) Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes. Cell Mol Immunol 6: 97-103.
29. Tanaka M, Kawaguchi Y, Yokofujita J, Takagi M, Eishi Y, et al. (1999) Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan. Virus Genes 19: 103-111.
30. Rickinson AB, Moss DJ, (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 15: 405-431.
31. Khanna R, Moss DJ, Burrows SR, (1999) Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 170: 49-64.
32. Liu G, Yao K, Wang B, Chen Y, Zhou F, et al. (2009) Immunotherapy of Epstein-Barr virus associated malignancies using mycobacterial HSP70 and LMP2A356-364 epitope fusion protein. Cell Mol Immunol 6: 423-431.
33. Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, et al. (2010) A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 116: 3695-3704.
34. International Agency for Research on Cancer WHO (1997) Epstein-Barr virus: summary of data reported and evaluation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans; Volume 70 Lyon IARC Press pp. 255-262.
35. Lung ML, Lam WP, Sham J, Choy D, Yong-Sheng Z, et al. (1991) Detection and prevalence of the "f" variant of Epstein-Barr virus in southern China. Virology 185: 67-71.
36. Lung ML, Chang RS, Huang ML, Guo HY, Choy D, et al. (1990) Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in southern China. Virology 177: 44-53.
37. Chen JN, Ding YG, Feng ZY, Li HG, He D, et al. (2010) Association of distinctive Epstein-Barr virus variants with gastric carcinoma in Guangzhou, southern China. J Med Virol 82: 658-667.
38. Zeng MS, Li DJ, Liu QL, Song LB, Li MZ, et al. (2005) Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol 79: 15323-15330.
39. Sinning C, Schaefer N, Standop J, Hirner A, Wolff M, (2007) Gastric stump carcinoma- epidemiology and current concepts in pathogenesis and treatment. Eur J Surg Oncol 33: 133-139.
40. Safatle-Ribeiro AV, Ribeiro U Jr, Reynolds JC, (1998) Gastric stump cancer: what is the risk? Dig Dis 16: 159-168.
41. Yamamoto N, Tokunaga M, Uemura Y, Tanaka S, Shirahama H, et al. (1994) Epstein-Barr virus and gastric remnant cancer. Cancer 74: 805-809.
42. Chang MS, Lee JH, Kim JP, Kim HS, Lee HS, et al. (2000) Microsatellite instability and Epstein-Barr virus infection in gastric remnant cancers. Pathol Int 50: 486-492.
43. Baas IO, van Rees BP, Musler A, Craanen ME, Tytgat GN, et al. (1998) Helicobacter pylori and Epstein-Barr virus infection and the p53 tumour suppressor pathway in gastric stump cancer compared with carcinoma in the non-operated stomach. J Clin Pathol 51: 662-666.
44. Chen JN, Jiang Y, Li HG, Ding YG, Fan XJ, et al. (2011) Epstein-Barr virus genome polymorphisms of Epstein-Barr virus-associated gastric carcinoma in gastric remnant carcinoma in Guangzhou, southern China, an endemic area of nasopharyngeal carcinoma. Virus Res 160: 191-199.
45. Lauren P, (1965) The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand 64: 31-49.
46. Japanese Gastric Cancer Association (1998) Japanese Classification of Gastric Carcinoma- 2nd English Edition. Gastric Cancer 1: 10-24.
47. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847.
48. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6: 2743-2751.
49. Busson P, Edwards RH, Tursz T, Raab-Traub N, (1995) Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. J Gen Virol 76 (Pt 1): 139-145.
50. Franken M, Annis B, Ali AN, Wang F, (1995) 5′ Coding and regulatory region sequence divergence with conserved function of the Epstein-Barr virus LMP2A homolog in herpesvirus papio. J Virol 69: 8011-8019.
51. Saiki Y, Ohtani H, Naito Y, Miyazawa M, Nagura H, (1996) Immunophenotypic characterization of Epstein-Barr virus-associated gastric carcinoma: massive infiltration by proliferating CD8+ T-lymphocytes. Lab Invest 75: 67-76.
52. van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, et al. (2006) Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol 30: 59-65.
53. de Campos-Lima PO, Gavioli R, Zhang QJ, Wallace LE, Dolcetti R, et al. (1993) HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science 260: 98-100.
54. de Campos-Lima PO, Levitsky V, Brooks J, Lee SP, Hu LF, et al. (1994) T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med 179: 1297-1305.